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Major pharmaceutical companies are placing significant emphasis on reducing spiralling R&D 
expenditures and improving productivity and this paper is directed towards helping this being 
achieved.  Clinical trials cost estimates positively affect the quality of stop/go decision making in late 
stage clinical development. The major quantitative challenge has been identified as how to estimate 
a priori the cost of clinical trials and prior research on this subject has been based upon a limited 
sample of drugs in development and depends upon average cost data released by the industry  
 
The contention here is that the application of parametric cost analysis to pharmaceutical 
development can help reduce the uncertainty and the degree of approximation of the cost estimates. 
By shifting the research objective from proprietary accounting information to simple and publicly 
available non-cost variables, the parametric model takes cost accounting for pharmaceutical R&D 
to a new level of methodological simplicity and statistical significance.  
 
1. Introduction 
Pharmaceutical development is a complex, risky and time-
consuming process. In a substantial majority of cases, 
pharmaceutical companies abandon research on new drugs 
that have undergone clinical testing but not received 
marketing approval. The extent and speed at which the 
development process makes new therapies available to the 
public are important measures of the viability of that 
process. The time required to take a new drug from 
synthesis to U.S. marketing approval has increased from 
approximately 8 years in the 1960s to approximately 14.2 
years in the 1990s (DiMasi, 1991).  The probability of a 
New Molecular Entity (NME) in development reaching 
the market increases with each successive phase of the 
R&D process. It is estimated that 60 percent of the active 
substances currently in discovery will not progress to the 
more advanced stages of development. These high 
attrition rates are a major challenge for the industry in the 
face of demands for increased productivity of NMEs 
(Findlay & Kernani, 2000).  
Major pharmaceutical companies are placing 
significant emphasis on the drive to reduce spiralling 
R&D expenditure and improve productivity. The 
optimisation of stop-go decisions is a strategy aimed at a 
direct and immediate reduction in expenditure. 
Knowledge of the principles of stop-go decision points 
within the R&D process is therefore of prime importance 
and by making a careful last-minute decision on a 
development candidate just before it enters clinical 
development, a company can reduce considerable wasted 
effort and resources on those projects with lower 
anticipated chances of viability, and so maximise the 
numbers of candidates that complete clinical trials and 
subsequently prove successful (Datamonitor, 1997).  
 2. Modelling the Value of R&D projects 
Pearson (1972) simply described the clinical innovation 
model using the sequential characteristics of decision 
analysis. In what follows we will review this and place it 
in context from the perspective of modelling the value of 
R&D projects.  
Suppose the development program of a new drug 
includes clinical trials 1, 2 and 3 and that all the trials 
must be positive for the drug to be registered. Let p1, p2 
and p3 be the probabilities of a positive outcome for the 
three trials. Let c1, c2 and c3 be their costs. Let C be the 
total expected net present cost of clinical development and 
let V be the value of the new drug if all trials show a 
positive outcome (Gittins, 1986). 
If the trials are carried out in the order 1 2 3 and they 
are halted as soon as one of them is negative, then: 
 
C = c1 + p1c2 + p1p2c3,   (1) 
V = p1p2p3v – c1 – p1c2 – p1p2c3, (2) 
Profitability Index = I = V/C  (3) 
  
The sequence that maximises I is the one that 
minimises C. Given a number of potential new drugs in 
the pipeline, with different success probabilities, costs and 
potential values, the Index values pick out those potential 
new drugs which should be given priority. In this 
admittedly oversimplified model, when a trial has a 
positive outcome the index takes a higher value than its 
value before the test. 
The approach to financial evaluation of drug 
development has been progressively rationalised, in 
parallel with the development of financial and risk 
analysis quantitative models. Looking at the evolution of 
R&D risk-adjusted models, financial evaluation has 
progressively moved away from deterministic quantitative 
analysis in favour of non-linear, stochastic algorithms 
(Favato, 2001). 
R&D projects are characterised by contingent decisions 
that depend on future outcomes. Conceptually, investing 
in the next R&D milestone can be considered as investing 
in a call option as regards the forthcoming step and its 
outcome and eventually the final outcome. Divestiture can 
be conversely considered as a put option.  
The value of managerial flexibility and the upside 
potential of risk are not properly captured by traditional 
Discounted Cash Flow (DCF) analysis: while higher risk 
translates into higher discount rates in traditional 
discounted cash flow models, Real Options evaluation 
rewards the acceptance of risk by properly valuing the 
upside potential (Bode-Greuel, 2002).  Nevertheless, Real 
Options can be viewed as complementing DCF analysis if 
DCF is applied in a dynamic way and takes into account 
that the R&D process is organised along milestones at 
which management will decide whether to abandon or 
continue the project. The possible outcomes can be 
displayed in decision trees and risk represented in 
probability estimates derived from average industry-
attrition rates.  
Real Options evaluation can also replace DCF: 
financial option pricing methods can be applied in order to 
evaluate projects. In this case, risk is represented in the 
assumed spread of asset value (binomial option pricing) or 
in a volatility parameter (Black & Scholes, 1972). 
Continuous-time option pricing algorithms based on the 
Black-Scholes model have also been proposed for the 
evaluation of R&D projects in the pharmaceutical industry 
(Trigeorgis, 1996).  
A great emphasis has been placed on the determination 
of streams of future cash flows, adjusting the present value 
for time and risk with probability functions, while little 
attention has been paid to the second driver of value: the 
cost of clinical trials. A major and contentious issue is 
whether the cost of a clinical trial be determined a priori 
with a sufficient degree of statistical confidence. 
3. Cost of clinical development: a 
controversial matter 
DiMasi et al. (2002) calculated the research and 
development cost of 68 new drugs obtained from a survey 
of 10 pharmaceutical companies. These data were used to 
calculate the average pre-tax costs of new drug 
development and the costs of compounds abandoned 
during clinical testing were linked to the costs of 
compounds that obtained marketing approval. The 
estimated out-of-pocket cost per new drug was $403 
million (2000 dollars), while the capitalized cost 
discounted at a rate of 11% per year reached a total of 
$802 millions. The average capitalized cost of pre-clinical 
R&D was $335 million and clinical research was 
confirmed as being the most expensive stage of 
pharmaceutical innovation, with $467 million being 
invested on average to bring a new medicine to market.  
When compared to the results of an earlier study with 
an identical methodology (DiMasi, 1991), total capitalized 
costs were shown to have increased at an annual rate 7.4% 
above general price inflation (average cost per NCE of 
$312 million in 1990 dollars). The 1991 DiMasi estimate 
constituted a 129 percent increase in costs over an 
estimate calculated by Hansen (1979) on products entering 
clinical trials between 1963 and 1975.  One quarter of the 
increase can be seen to reflect the longer time periods, two 
thirds to reflect the increase in out-of-pocket costs, and the 
balance to reflect DiMasi et al.’s use of a higher cost of 
capital (9 percent rather than 8 percent). 
Given the importance of this issue, it is important to 
note that many have questioned the DiMasi research. First, 
critics say it is troublesome to apply so much of the 
industry data, because industry trade associations have 
incentives to exaggerate costs of all aspects of R&D. 
Secondly, critics maintain that taxpayers actually pay for 
much of the cost of preclinical and clinical research and 
thirdly, the assumptions regarding clinical expenditures 
are not supported by any project-level data. 
Of the three areas of concern, the last is particularly 
important, first because there is the issue of which concept 
of cost should be considered, distinguishing between 
average and marginal (or additional) costs of clinical 
development. The various dimensions of therapeutic 
benefit are definitely related to the costs required to prove 
those benefits in controlled clinical trials leading to 
 marketing approval. Furthermore clinical development 
costs may be quite different depending on the degree of 
innovation shown by each individual new drug 
investigated. 
In reality the most important peculiarity of clinical 
pharmaceutical research is the significant variability in the 
number of patients required by the U.S. Food and Drug 
Administration (FDA), to grant marketing approval. The 
number of patients enrolled in registration for clinical 
trials represents the closest proxy to the total cost of 
clinical development.   The reason for this is that the 
protocol requirements of randomised studies makes cost 
relatively similar irrespective of purpose and minimises 
the cost differences among therapeutic areas. In other 
words, a patient included in a cancer study costs the same 
as a patient enrolled in an allergic rhinitis (common cold) 
trial. Therefore, if a product is approved with a 
significantly lower number of patients in the regulatory 
database than another one, it necessarily means that the 
cost of development of the first one is significantly lower 
than the second one. To understand the implications of 
this let’s consider the following situation. 
In May 1996, Gemzar (gemcitabine) by Eli Lilly & Co. 
received approval by the FDA for the treatment of patients 
with inoperable pancreatic cancer. Gemzar, one of the 
most innovative cancer chemotherapies made available in 
the past few years, demonstrated clinical efficacy in two 
studies of 69 and 126 patients with locally advanced or 
metastatic pancreatic cancer (FDA Bulletin, 05/15/96).   
On December 27th, 2001 Schering Plough announced that 
a new drug application was submitted to FDA seeking the 
approval of Zetia (ezetimibe), a cholesterol absorption 
inhibitor. Zetia is the first compound in a new class of 
lipid lowering agents that inhibits the intestinal absorption 
of cholesterol in patients with hypercholesterolemia. In 
controlled clinical studies, over 8,000 patients were 
exposed to the treatment with Zetia for over two weeks 
(Schering Plough press release, January 2002). It requires 
no specialist understanding of finance to understand that 
the difference in the relative cost incurred by each of these 
two clinical programmes enrolling respectively 195 and 
over 8,000 patients was enormous.  
Why did Zetia need so many patients to get marketing 
approval? The answer is embedded in the theory of 
clinical trial planning: the sample size required for clinical 
development of new pharmaceuticals can be determined a 
priori as a function of the smallest significant clinical 
outcome to be proved. It is to this issue that attention will 
now be directed. 
4. Clinical sampling methodology 
The randomised, controlled trial is the benchmark for the 
evaluation of new drug therapies. Random allocation is a 
powerful means of controlling for the potential effects of 
confounders and serves to minimize bias (systematic 
deviation from the truth) on the part of physicians and 
patients. In clinical trials it is also vital that investigators 
choose as a primary measure of response an outcome that 
is clinically meaningful (delta). In the past there has been 
an over-reliance on surrogate markers of efficacy such as 
improvements in laboratory tests and in some instances 
these have been shown not to correlate with clinically 
meaningful outcomes. The reality is that investigators 
should consider use of quality of life measures as 
measures of response in addition to the more conventional 
outcomes of death, occurrence of disease-related 
complications and clinical activity indices (Hulley et al., 
2003). Nevertheless, an appropriate outcome has been 
identified, but the planning of a clinical trial requires input 
from a bio statistician. Careful consideration has to be 
given to the number of patients required, which is 
dependent upon the alpha (false positive) and beta (false 
negative) error rates selected by the investigator, the size 
of treatment effect that is considered to be clinically 
meaningful and the estimated rate of occurrence of the 
outcome of interest in the placebo (or standard therapy) 
group. If interim analyses are planned, these must be 
defined prior to initiation of the study, and appropriate 
statistical techniques employed to account for the increase 
in the alpha error rate that results from the use of multiple 
statistical testing procedures (Kazdyn, 2002). 
Wooding (1984) identified four non-cost variables 
driving sample size and therefore the cost of 
pharmaceutical research in humans; these were the critical 
difference (δ), risk of failing to detect a difference greater 
than delta (β), the risk of falsely claiming that a difference 
exists (α), the estimated expected experimental error (s). 
Delta (δ) is the minimum population difference that the 
clinical researchers wish to be detectable using a 
hypothesis test to compare data from two samples. This 
difference represents the smallest difference of interest 
clinically. The following is an example for a two-tailed 
test: 
 
H0: μ1 – μ2 = 0  (4)  
 H1: | μ1 – μ2 |= δ  (5)   
 
In the test of the null hypothesis of equation (5), the 
investigator wishes to test for significance to determine 
whether to reject that hypothesis. 
Alpha (α) is the probability of being wrong if that test 
leads the researcher to claim significance (e.g., if the 
researcher states that two treatment group averages are 
different by an amount delta, favouring one or the other 
treatment). 
Beta (β) is the probability of being wrong if the test 
leads the researcher to claim that no difference of delta or 
greater exists between the two group means. 
Sigma (σ) is the estimate of the experimental error or 
variation of each measurement, on average. 
The recommended procedure includes the specification 
“a priori” of beta and alpha risks, as well as a value for 
delta and an estimate of sigma. As the FDA is reluctant to 
accept significance tests using alpha values that exceed 
0.05 and beta values lower than 0.20 as primary evidence 
of efficacy and safety, the sample size is simply a function 
of the effect size, the critical difference over variance 
(δ/s). In the following table, Wooding (1984) reported the 
calculated number of patients per treated arm ranked by 
effect size values, at a level of significance of alpha equal 
to 0.05 and beta equal to 0.20. In order to obtain the total 
 number of patients enrolled, the calculated sample size 
needs to be doubled, as most clinical trials are 
comparisons of two mean values. 
 
Effect size Patients/arm 
0.40 100 
0.45 79 
0.50 64 
0.55 53 
0.60 45 
0.65 39 
0.70 34 
0.75 29 
0.80 26 
0.85 23 
0.90 21 
0.95 19 
1.00 17 
1.10 14 
1.20 12 
1.30 11 
1.40 10 
1.50 9 
1.60 8 
1.70 7 
1.80 6 
1.90 6 
2.00 6 
2.10 5 
2.20 5 
2.30 5 
2.40 4 
2.50 4 
3.00 4 
3.50 3 
 
Table 1. Sample sizes ranked by effect size for a two-tailed test of 
comparison of two means, with alpha= 0.05 and beta= 0.20. 
 
A unique implication of the use of clinical experimental 
design is the possibility to derive a mathematical equation 
that estimates a priori the number of patients (the closest 
proxy of cost) required to test the chosen clinical outcome 
accurately.   In simple terms this involves the derivation of 
parametric costs and in what follows the application of 
parametric cost analysis to pharmaceutical clinical 
development is demonstrated as being a useful tool to 
reduce the uncertainties related to cost estimates. 
DiMasi et al. (2002) 
5. Parametric cost analysis 
Parametric Cost Analysis establishes a clear linkage 
between cost and a product's technical non-cost 
parameters by using equations to map measurable system 
attributes onto cost (Dean, 2000). The measures of the 
system attributes are called “metrics”. The equations are 
called “cost estimating relationships” (CER) and are 
obtained by the analysis of cost and technical metric data 
of products that are analogous to those to be estimated. 
Johnston (1960) provides foundational theory, methods 
and results on case studies. Klein and Tait (1971), in an 
early example of applied parametric cost analysis to a 
business as distinct from a research and development 
problem, expressed the number of tool-design and tool-
fabrication hours per part in terms of the number of drilled 
and reamed holes, the volume of the piece, the number of 
locating points, and the complexity of part orientation. 
The authors used step-wise regression to select, from the 
eleven chosen as possible cost drivers, these statistically 
significant variables for a linear equation. The authors also 
introduced the reality of cost uncertainty through a trade-
off of confidence and expected time. 
Today, parametric estimating is typically applied to 
large systems, such as those found in the U.S. Department 
of Defence or NASA (2001). Parametric estimating relies 
on simulation models that are systems of statistically and 
logically supported mathematical equation that defines the 
impact of a product’s physical, performance and 
programmatic attributes on cost and schedule. Tailoring 
parameters are used to describe the object being estimated 
and the output of the model is validated with data from 
past projects. The object to be estimated is described by 
choosing specific values for the independent variables in 
the equation that represents the characteristics of the 
object. The equations are then used to extrapolate from 
past and current experience to forecast the cost of future 
products. 
The fundamental assumption in parametric cost 
analysis is that a measurable relationship exists between 
system attributes and the cost of the system: if a function 
exists, the attributes are cost drivers. Sample-size 
variables are constraints on the clinical development 
process (Wooding 1984). From optimisation theory it is 
known that any active constraint generates cost by not 
permitting full optimisation of the objective and sample-
size variables are cost drivers. 
The typical statistical process is to find a value for m 
parameters p = (p1 … pk) such that the cost y can be 
predicted reasonably well by the equation: 
 
  y = f (x, p) + e   (6) 
 
where e is the prediction error and x = (x1 … xm) is a 
set of measures of system characteristics that vary over n 
cases (yi x1i … xmi), different for each i = 1, n. 
CER is a mathematical expression relating cost as the 
dependent variable to one or more independent cost-
driving variables. 
6. Developing a Cost Estimating Relationship 
(CER) model for clinical trials. 
The basic process of developing a parametric model 
can be simplified using four fundamental steps (Dean, 
2000):  
1) cost model scope determination;  
2) data collection; 
3) data analysis and testing; 
4) data application. 
  
Step 1: cost model scope determination. 
Developing a simplified parametric model is to 
establish its scope, which includes defining the end use of 
the model, the cost basis of the model and its critical cost 
drivers. The pharmaceutical innovation cost model is 
derived by the randomised clinical trials sampling theory 
(Wooding, 1984), where the sample size is a function of 
four non-cost variables: critical difference (δ), risk of 
failing to detect a difference greater than delta (β), the risk 
of falsely claiming that a difference exists (α), the 
estimated expected experimental error (s). If considered in 
terms of pharmaceutical clinical research, alpha (0.05) and 
beta (0.20) are constant. The effect size, the normalised 
non-cost parameter, is equal to delta in terms of the 
number of estimated expected experimental error and it is 
calculated by dividing the specified delta value by the 
estimated value of sigma (δ/s). In the simplified case of 
regulatory clinical trials, where alpha and beta are 
constant, the sample size is function of the effect size, the 
standardised minimal significant outcome.   In its specific 
application to pharmaceutical innovation model, the 
derived CER would estimate the cost of clinical trials 
apparently relate two non-cost variables (effect size and 
sample of patients). Actually the number of patients 
required for outcomes to be significant is a defined proxy 
for the total direct costs of a clinical trial. The dollar 
amount per patient can be estimated on the base of the 
average all-inclusive fee charged for each clinical patient 
enrolled by the external clinical research organizations 
(CROs), which generally are contracted by pharmaceutical 
companies to conduct global clinical trials.  
 
 
Step 2: data collection. 
The data collection and development of a parametric 
model requires significant effort and the quality of the 
resulting parametric model can be no better than the 
quality of the data it is based upon. To derive a CER 
model for clinical development, the sample sizes 
calculated by Wooding (1984, reported in Table 1) are 
adequate but a larger database of sampling data from 
published randomised clinical trial would be indispensable 
to obtain a more reliable estimate of clinical trials cost. In 
short, Parametric Cost Analysis extrapolates future costs 
from past non-cost data.  
As regards pharmaceutical research and development, 
clinical trial protocols designed for registration are 
negotiated with the FDA, which therefore reflect the 
agency perspective on sample size required to grant a 
NME marketing approval. . FDA priorities go well beyond 
medical statistics and depending on the nature of the 
investigational drug, it is willing to tolerate safety risks in 
favour of clinical efficacy. If the therapeutic area is very 
severe, with limited treatment alternatives currently 
available, the FDA might be willing to approve a drug 
exposed to very few patients: that was the case of Xigris 
(Eli Lilly & Co.) approved in January 2002 for treatment 
of severe sepsis with a dossier of less than 700 patients 
(FDA - The Pink Sheet, 2002). Discussions with the FDA 
are not centred on the minimal clinically significant 
outcome (delta) but rather on standard error assumptions. 
In medicine the standard error is rarely pre-determined on 
the base of large epidemiological evidences. Standard 
errors are based on previously published trials and limited 
population data and very often the FDA requires a sample 
size large enough to support the validity of outcomes with 
standard errors much smaller than the one used for 
academic trials. A Cost Estimating Relationship derived 
from a significant sample of past clinical protocols would 
reflect the variety of FDA approaches to grant marketing 
approval. It would also provide an estimate that is not 
“exact”, but at the same time is based on the specific 
cohort of clinical trials, with all the variables and caveats 
of a negotiation process. 
 
Step 3: data analysis and testing. 
 The General Linear Model describes the various 
factors that influence an individual score (on the 
dependent variable) in an investigation. In linear 
regression analysis, a single independent variable (X) is 
used to estimate the dependent variable (Y), and the 
relationship is assumed to be linear (a straight line).  This 
is the most common form of regression analysis used in 
CER development. Before developing a mathematical 
equation, a data plot may suggest the type of relationship 
among points (linear, log-linear, and exponential) and note 
any points that may require further investigation. 
  
 
 
 
Figure 1. Scatter plot of Wooding sample variables (Table 1) 
 
The graphical relationship between effect size and 
relative sample size calculated by Wooding (1984) (See 
Figure 1) seemed to suggest a curvilinear, probably 
logarithmic relationship between the two variables. This is 
not a general relationship but is the drawn from the 
randomised clinical trials sampling theory. The rationale 
for this is that the sample size increases exponentially as 
the variable to be observed becomes smaller (Wooding, 
1984). As Parametric Cost Analysis recommends the use 
of simple linear regression to derive the CER (ISPA, 
2001), both variables were transformed in their 
logarithmic equivalent. The trend line for the logarithmic 
transformation of both dependent and independent data 
was derived by least squares and has the formula: 
Wooding table variables scatter plot
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
0 20 40 60 80 100 120
sample size
e
ff
e
c
t 
s
iz
e
  
   log sample size = 1.266 + (-1.665 x log effect size) (7) 
 
The independent variable is the effect size (delta/s): the 
effect size describes the minimal detectable difference (δ) 
over the estimated variance (s). The dependent variable is 
the calculated number of patients per treated arm. 
Applying this formula to any effect size decided a priori 
by the investigator yields computed number of patients 
(sample size) per treated arm. In clinical research, an arm 
is a group of patients receiving the same treatment 
(investigational drug or placebo). Usually comparative 
trials have two arms, but the adoption of protocols with 
three or four treatment groups is not infrequent.  
 
As an illustrative example, let’s assume that a planned 
two arm clinical trail has the effect size of 0.65. Plugging 
the effect size into the CER equation (7), the expected 
sample size of the study is 76 patients (38 patients in each 
of the two arms). If the study protocol is designed in 3 
arms, the expected sample size would be 114 patients (38 
patients x 3 arms). 
The evaluation of the CER quality is the most critical 
step in the Parametric Cost Estimating process. When 
testing the precision of a model, the most often cited 
statistic is the coefficient of correlation R-square, which is 
the correlation between the dependent and the independent 
variables. A strong correlation (an R-square value above 
0.7) indicates good prediction. The R-square for the CER 
derived from the Wooding data sample is 0.989, 
indicating that the relationship is essentially linear. It 
seems unlikely that relevant variables have been excluded, 
based on the Wooding (1984) sample theory for 
randomised clinical trials, however, it is also prudent to 
check the F statistic, which indicates whether the model as 
a whole is significant. The CER derived from the linear 
regression of the log-transformed variables proved to be a 
statistically significant cost estimating model (F value 
2457.903, P<0.001). Lastly, the standard error of the 
estimate (SSE) is examined to ascertain how much 
dispersion there is in the equation. If the CER equation is 
used to predict the number of patients per treated arm, 95 
percent of the predictions will fall within two SSE of the 
predicted value. The very small SSE value of the derived 
CER (0.05) would suggest an elevated degree of reliability 
of the cost predicting linear equation.  
The derived CER satisfied the fundamental 
assumptions of regression: the negative correlation shown 
between effect size and sample size is extremely 
significant (p< 0.01): therefore, in clinical trials, effect 
size and sample size are linearly correlated.  
 
Step 4: data application: a case example. 
The research activity of a biotech company led to the 
discovery of a new neuroprotective compound showing a 
novel mechanism of action (Bode-Greuel, 1997). Pre-
clinical studies indicated a potential clinical activity on 
degenerative diseases of the peripheral nervous system, 
such as diabetic neuropathy. In the absence of official 
registration guidelines for neuropathy, the biotech 
company negotiated with the FDA a clinical development 
plan requiring three comparative clinical studies to prove 
the following endpoints: 
1. short term tolerability and symptomatic improvement; 
2. improved nerve conduction velocity; and 
3. long term tolerability and delay in neurological   
    deterioration. 
Table 2 summarises the relevant parameters of each 
study. 
 
 
Clinical studies required by 
FDA 
Effect size Probability of 
success 
Study 1: short term 
tolerability and symptomatic 
improvement 
0.5 22% 
Study 2: improved nerve 
conduction velocity 
0.2 14% 
Study 3: long term tolerability 
and delay in neurological 
deterioration 
0.1 8% 
 
 
Table 2. Clinical trials parameters for the development of a 
neuroproctetive new compound. 
 
 
By simply plugging the estimated effect size of each 
planned clinical trial into the derived CER equation 
(number!) it was possible to estimate a priori the number 
of patients per treated arm required to prove the minimal 
significant outcome. Table 3 summarizes the estimated 
direct costs of each clinical trial, assuming a standard net 
present cost per patient of $30,000. 
 
 
Trial Effect 
size 
CER est. 
patients 
per arm 
Study 
arms 
Standard 
cost per 
patient 
 
Cost of 
trial 
$ mill 
1 0.5 58 2 $30,000 $3.48 
2 0.2 269 2 $30,000 $16.14 
3 0.1 853 2 $30,000 $51.18 
 
 
Table 3. Estimated net present cost of clinical trails using the derived 
CER and a standard cost per patient of $30,000. 
 
 
The total estimated cost of clinical development for the 
new neuroprotective agent is $70.8 million.  
 How can a reliable estimate of clinical costs help 
the management of the biotech company to make a 
decision on the development of the new drug?    
The answer is assuming that the net present value 
(NPV) of an approved new treatment of diabetes 
neuropathy is estimated to be $1.5 billion, that all the 
three planned trials must be positive to get marketing 
approval, and that the trials are carried out in the order 1 2 
3, their estimated cost is c1, c2, c3, their relative success 
probability is p1, p2, p3 and they are halted as soon as one 
of them is negative, then the expected value of the project 
(V) is obtained by solving the following equation (Gittins, 
1986): 
 
V = p1p2p3v – c1 – p1c2 – p1p2c3   (2) 
 V = (0.22 x 0.14x 0.08 x 1,500,000,000) – 3,480,000 –      
       (0.22 x 16,140,000) –  (0.22 x 0.14 x 51,180,000) 
V = 3,696,000 – 3,480,000 – 3,550,000 – 1,576,344
    
V = - 4,910,344    
       
 
Regardless of the estimated market reward for 
innovation in diabetes neuropathy ($1.5 billion), the net 
present expected value is negative, due to the small 
cumulative probability of successful clinical development 
(p1 x p2 xp3 = 0.25%), reducing the expected revenues to 
a mere $3.70, and to the high expected cost of the three 
clinical trials required to obtain regulatory approval 
(respectively $3.48, $3.56 and $1.58 million, adding up to 
a total development cost of $8.62 million). 
The biotech company should decide to halt this 
potentially innovative project due to the elevated expected 
costs of clinical development and the high risk of failure. 
7. Conclusions 
The methodological objective of this paper was to remove 
the two principal threats to validity of the existing clinical 
trial cost estimating literature (Love, 2000): the small 
number of development candidates in the sample and 
reliance upon unverifiable “average” cost data supplied by 
the industry. In order to improve the external validity 
(sample size), it is critical to look for new variables to be 
used as proxies for the information on average costs, but 
more easily accessible to the researcher. Theory 
determines the choice of variables to be observed.  
The application of parametric estimating methods to the 
pharmaceutical development process allows the estimation 
of clinical trials direct costs from a derived linear 
relationship. The derived Cost Estimating Relationship 
(CER) correlates the effect size (in other words the 
standardised minimal significant outcome, which is a 
known a priori independent variable) to the minimal 
sample-size required to confer statistical significance upon 
the outcome (independent variable). The parametric 
methodological perspective actually looks at the sample 
size theory as a linear relationship to pre-determine the 
cost of research. The possibility to estimate the cost of late 
stage clinical development with an elevated degree of 
confidence would definitely improve the quality of stop/go 
decisions and portfolio evaluation in pharmaceutical 
R&D. 
Establishing a relationship between cost and non-cost 
parameters, the parametric model moves away from the 
classical post-hoc cost-accounting analysis, full of 
assumptions and complex allocations, towards a forward 
looking estimate of future direct-research costs, derived as 
a dependent variable from a linear Cost Estimating 
Relationship (CER). The effect size, the minimal 
standardised clinical significant outcome, has been 
considered as the independent variable that drives the 
clinical trial protocol (Wooding, 1984). It is determined a 
priori by the investigators and it is included in the 
publication as a critical element to evaluate the statistical 
significance of the outcome. Shifting the cost estimating 
methodology from proprietary accounting information to 
simple and publicly available variables, the parametric 
model takes the costing research of pharmaceutical 
development to a new level of simplicity and statistical 
significance. 
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